US provides Ebola treatment for outbreak in Congo, bringing trials closer

The U.S. has supplied an experimental antibody drug from Mapp Biopharmaceutical to help tackle the growing Ebola outbreak in the Democratic Republic of Congo, which is crucial as it brings clinical trials closer to reality. This intervention is significant as it highlights international efforts to combat the virus and could potentially lead to more effective treatments. The move underscores the global health community's urgency in addressing the outbreak, which is spreading rapidly in a region with limited healthcare infrastructure.